27 research outputs found

    c-Myc and AMPK Control Cellular Energy Levels by Cooperatively Regulating Mitochondrial Structure and Function.

    Get PDF
    The c-Myc (Myc) oncoprotein and AMP-activated protein kinase (AMPK) regulate glycolysis and oxidative phosphorylation (Oxphos) although often for different purposes. Because Myc over-expression depletes ATP with the resultant activation of AMPK, we explored the potential co-dependency of and cross-talk between these proteins by comparing the consequences of acute Myc induction in ampk+/+ (WT) and ampk-/- (KO) murine embryo fibroblasts (MEFs). KO MEFs showed a higher basal rate of glycolysis than WT MEFs and an appropriate increase in response to activation of a Myc-estrogen receptor (MycER) fusion protein. However, KO MEFs had a diminished ability to increase Oxphos, mitochondrial mass and reactive oxygen species in response to MycER activation. Other differences between WT and KO MEFs, either in the basal state or following MycER induction, included abnormalities in electron transport chain function, levels of TCA cycle-related oxidoreductases and cytoplasmic and mitochondrial redox states. Transcriptional profiling of pathways pertinent to glycolysis, Oxphos and mitochondrial structure and function also uncovered significant differences between WT and KO MEFs and their response to MycER activation. Finally, an unbiased mass-spectrometry (MS)-based survey capable of quantifying ~40% of all mitochondrial proteins, showed about 15% of them to be AMPK- and/or Myc-dependent in their steady state. Significant differences in the activities of the rate-limiting enzymes pyruvate kinase and pyruvate dehydrogenase, which dictate pyruvate and acetyl coenzyme A abundance, were also differentially responsive to Myc and AMPK and could account for some of the differences in basal metabolite levels that were also detected by MS. Thus, Myc and AMPK are highly co-dependent and appear to engage in significant cross-talk across numerous pathways which support metabolic and ATP-generating functions

    Ribosomopathy-like properties of murine and human cancers

    No full text
    <div><p>Ribosomopathies comprise a heterogeneous group of hematologic and developmental disorders, often characterized by bone marrow failure, skeletal and other developmental abnormalities and cancer predisposition. They are associated with mutations and/or haplo-insufficiencies of ribosomal proteins (RPs) and inefficient ribosomal RNA (rRNA) processing. The resulting ribosomal stress induces the canonical p19<sup><i>ARF</i></sup>/Mdm2/p53 tumor suppressor pathway leading to proliferative arrest and/or apoptosis. It has been proposed that this pathway is then inactivated during subsequent neoplastic evolution. We show here that two murine models of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) unexpectedly possess features that mimic the ribosomopathies. These include loss of the normal stoichiometry of RP transcripts and proteins and the accumulation of unprocessed rRNA precursors. Silencing of p19<sup><i>ARF</i></sup>, cytoplasmic sequestration of p53, binding to and inactivation of Mdm2 by free RPs, and up-regulation of the pro-survival protein Bcl-2 may further cooperate to drive tumor growth and survival. Consistent with this notion, re-instatement of constitutive p19<sup><i>ARF</i></sup> expression in the HB model completely suppressed tumorigenesis. In >2000 cases of human HCC, colorectal, breast, and prostate cancer, RP transcript deregulation was a frequent finding. In HCC and breast cancer, the severity of this dysregulation was associated with inferior survival. In HCC, the presence of RP gene mutations, some of which were identical to those previously reported in ribosomopathies, were similarly negatively correlated with long-term survival. Taken together, our results indicate that many if not all cancers possess ribosomopathy-like features that may affect their biological behaviors.</p></div

    Incomplete processing of rRNAs in HBs and HCCs.

    No full text
    <p>(A) Normal rRNA processing. Arrows depict regions amplified by qRT-PCR to quantify 18S-ITS1, ITS1-5.8S, 5.8S-ITS2 and ITS2-28S junctional fragments common to all rRNA precursors. (B) Quantification of each of the above four junctions in control livers and HBs. Identically colored dots represent the same tumor RNA sample within the subgroup of tumors that demonstrated abnormal processing of at least one junction. Control livers and tumors with no significant processing differences are depicted in black. (C) Similar quantification of RNA processing in HCCs. Data in (B) and (C) were normalized to levels of total 18S and 28S RNA. Each qRT-PCR reaction was performed in triplicate and the mean is depicted.</p

    RP transcript deregulation in human cancers.

    No full text
    <p>3D area maps of transcript levels for 77 RPs expressed in HCCs (A), CRCs (B), BCs (C) and PCs (D). To better evaluate differences in the other transcripts which did reach significance for their F-tests, these transcripts–<i>Rps26</i>, <i>Rpl9</i>, <i>Rps27</i>, <i>Rps28</i>, and <i>Rpl21</i>– were excluded from 3D area plots. For each cancer, tumors with matched samples of normal tissue in TCGA were selected for direct comparison (50 for HCC, 41 for CRC, 113 for BC and 52 for PC). Relative expression for each RP transcript was calculated as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182705#pone.0182705.g001" target="_blank">Fig 1</a>. See Figures D-G in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182705#pone.0182705.s001" target="_blank">S1 File</a> for 3D area plots of the above matched tumor data together with additional data from unmatched tumor samples. (E, F) Patient survival in HCC and BC inversely correlates with the severity of RP transcript deregulation. Patients were sorted according to their RP transcript deregulation, and survival curves were plotted for the top and bottom 25% of patients with the greatest and least degree of RP transcript deregulation.</p

    Reprograming of survival and apoptosis pathways in HBs and HCCs.

    No full text
    <p>(A) Expression of p19<sup>ARF</sup>, MDM2 and p53 in total liver (L) and HB (T) lysates from WT and KO mice. (B) Similar immuno-blots from HCCs. (C) Immuno-staining of frozen sections of liver (L) and WT HBs (T) for p53 and MDM2. Using ImageJ software (<a href="https://imagej.nih.gov/ij/" target="_blank">https://imagej.nih.gov/ij/</a>), we determined that >80% of Mdm2 and p53 localized to the cytoplasm in both livers and tumors. (D) p53 and MDM2 co-localize to HB cytoplasm. A freshly collected WT HB tumor was fractionated into cytoplasmic, nuclear and nucleolar compartments. Each fraction was tested for the protein markers localizing to these compartments (GAPDH, histone H3 and fibrillarin, respectively) and in parallel for p53, p19<sup>ARF</sup> and MDM2. Varying amounts of lysate and exposure times were required to compensate for differential protein expression. (E) Liver and HB cytoplasmic fractions were immuno-precipitated with control IgG or anti-MDM2 IgG. Precipitates were resolved by SDS-PAGE and silver stained. Bracketed regions were excised from lanes 2 and 4 and subjected to trypsin digestion and mass spectrometry. (F) Bcl-2 and Bax expression in mitochondria from WT or KO HBs [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182705#pone.0182705.ref016" target="_blank">16</a>]. The same blot was probed with an antibody for the mitochondrial protein pyruvate dehydrogenase E1α subunit (PDH) as a control for protein loading. The mean up-regulation of Bcl-2 relative to that in livers was 3.8-fold in WT HBs and 2.3-fold in KO HBs. The mean up-regulation of Bax was 11.7-fold in WT HBs and 10.5-fold in KO HBs. (G) Bcl-2 and Bax expression in isolated mitochondria from livers (L), tumors (T) and recurrent HCC tumors [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182705#pone.0182705.ref012" target="_blank">12</a>]. The mean up-regulation of Bcl-2 was 5.5-fold in initial tumors and 6.3-fold in recurrent tumors. Similarly, the mean up-regulation of Bax was 15-fold in initial tumors and 15.6-fold in recurrent tumors.</p

    Relative RP transcript and protein levels differ in murine models of HB and HCC.

    No full text
    <p>(A) RP transcript abundance in hepatocytes (H) versus HB tumors (T). Heat maps are based on averaged RNA-seq data from 4–5 samples in each group with the most abundant transcripts being shown in orange and the least abundant transcripts being shown in blue, with the sum of all transcripts in each group equaling 100%. All transcript levels are expressed as a percent of total, displayed relative to those in WT hepatocytes and do not take into account the fact, as previously shown, that average RP transcript expression was increased 5.2-fold in HBs relative to hepatocytes [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182705#pone.0182705.ref016" target="_blank">16</a>] *: deregulated transcripts in WT tumors vs. WT hepatocytes, ^: deregulated transcripts in KO tumors vs. KO hepatocytes. (B) RP transcript deregulation among WT and KO hepatocytes and HBs. (C) Similar heat maps from livers or HCCs [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182705#pone.0182705.ref013" target="_blank">13</a>]. L: control livers. 3D and 7D: livers obtained 3 and 7 days after removing doxycycline to induce Myc expression. T: initial tumors. 3R and 7R: regressing tumors following doxycycline resumption for 3 or 7 days, respectively. Additional tumor-bearing mice were maintained on doxycycline for 2.5–3 months to allow for complete regression. Doxycycline removal in these mice led to development of recurrent tumors [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182705#pone.0182705.ref012" target="_blank">12</a>]. *: significant differences in relative expression compared to normal liver; ^: significant differences between recurrent tumor and liver (q-value < 0.05). Relative transcript abundance was expressed as described for panel A and compared with the relative abundance in control livers. (D) RP transcript discordances between HBs and HCCs. “Opposing” directionality occurred when an HB transcript’s direction of change relative to hepatocytes differed between WT and KO HBs. (E) Immunoblots of RPs in WT and KO livers (L) and HB tumors (T). (F) Immunoblots of RPs from livers, collected as described in (C).</p

    Model depicting the relationship between Myc and AMPK (yellow boxes) demonstrating their influence over common metabolic functions, although sometimes in opposite ways and for different purposes.

    No full text
    <p>Communication between Myc and AMPK may occur via at least 2 distinct and semi-autonomous routes with different initiating events and consequences. The first involves the activation of AMPK via Myc-mediated depletion of cellular ATP stores arising as a consequence of energy-consuming anabolic processes such as proliferation (-ATP, blue box) (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0134049#pone.0134049.g001" target="_blank">Fig 1D</a> and [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0134049#pone.0134049.ref023" target="_blank">23</a>]). The second involves AMPK activation via ROS generated from increases in mitochondrial metabolism or cytoplasmic signaling pathways. It is notable that, in the first case, AMPK activation is dependent upon ATP depletion whereas, in the second case, AMPK activation occurs regardless of ATP status. AMPK activation via ROS can thus anticipate impending ATP depletion and prevent or limit this by down-regulating ATP dependent processes. In the face of a pre-existing ATP deficit, other functions of AMPK such as the promotion of proliferative arrest might tend to override the effects of Myc over-expression. In contrast, activation of AMPK by ROS might reinforce an already highly proliferative and ATP-replete state by promoting pro-anabolic functions such as glycolysis and Oxphos without necessarily compromising proliferation.</p

    Redox states in cytoplasmic and mitochondrial compartments of WT and KO MEFs.

    No full text
    <p><i>(A)</i> Live cell confocal images of WT MEFs stably expressing roGFP-mito and roGFP-cyto demonstrating specific mitochondrial and cytoplasmic localization, respectively. Nuclear counter-staining was with Hoechst 3334. <i>(B)</i> Live cell confocal microscopy of KO MEFs expressing roGFP-mito. Cells were untreated or exposed to 1 mM H<sub>2</sub>O<sub>2</sub> or 10 mM DTT for 30 min prior to obtaining images. <i>(C)</i> Quantification of redox differences between WT and KO MEFs. Monolayer cultures were grown for 24 hr. in the absence or presence of 4HT. Flow cytometry was then used to quantify the mean fluorescence ratios of oxidized and reduced roGFP. Each bar represents the average ± 1 SEM of mean fluorescence intensities obtained from 3 independent plates of cells. * = P<0.001. Similar results were independently obtained in 2 repeat experiments as well as in 2 experiments performed following a longer period of MycER activation (7 days, not shown). The 4 bars on the right represent control experiments in which WT cells expressing roGFP-cyto were exposed under the conditions described in <i>(B)</i>. These values define the maximal possible degree of oxidation or reduction capable of being achieved under the most extreme conditions.</p
    corecore